ArticleEJIFCC2025
Evaluation of Serum Soluble CD36 Levels in the Clinical Progression of Diabetic Nephropathy.
Article in EJIFCC, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Diabetic nephropathy (DN) is one of the major contributors to end stage kidney disease globally. Reliable biomarkers for early diagnosis of DN still exists as a major challenge. Serum soluble CD36 (sCD36) involved in lipid metabolism and oxidative stress has been identified as a likely biomarker of DN. Herein, we assess the relationship between sCD36 and clinical worsening of DN, to determine its potential diagnostic value. Material and Methods: A case- control study involving 160 participants, categorized into four groups was conducted i.e., healthy individuals, diabetics with normo-albuminuria, microalbuminuria, and macroalbuminuria (n = 40).Demographic variables and biochemical parameters were compared. The concentrations of sCD36 in serum samples were determined, as well as correlation analysis between sCD36, fasting plasma glucose (FPG), HbA1c, urine albumin creatinine ratio (UACR), and estimated glomerular filtration rate (eGFR) were performed. The diagnostic performance of sCD36 was determined using receiver operating characteristic (ROC) curve. Results: Serum sCD36 levels rose progressively from 9.97 ng/mL in the control group to 12.13 ng/mL in the macroalbuminuria group, p < 0.001. Patients with higher sCD36 levels also had higher fasting plasma glucose, HbA1C, and UACR with a lower eGFR. The ROC analysis of sCD36 gave an AUC of 0.908, showing excellent diagnostic capability of the model. The optimal cut-off value of 10.6 ng/mL yielded 87.5 % sensitivity and 80.83% specificity for detecting advanced DN. Conclusion: Increased serum sCD36 levels correlates directly to DN progression, hence being a promising candidate biomarker for diagnosis and prognosis. The possible direct application of sCD36 into clinical practice might help improve DN management and treatment.
Indexed as
Identifiers
41459177PMC12743335What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.